NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch. Chief Executive Officer Michael Davidson said the | ||
 NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness Recent trading context for NewAmsterdam Pharma (NasdaqGM:NAMS) NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after recent trading, with the stock closing at US$29.33. The move comes alongside a month-long decline of about 26% and a year-to-date drop near 17%. See our latest analysis for NewAmsterdam Pharma. The recent 1 month share price return, down 25.92%, suggests momentum has cooled in the short term, even as the 1 year total shareholder return of 43.07% and very large 3... | ||
 Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026 We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Druckenmiller’s Stake: $98,275,000 Druckenmiller likes asymmetric bets where he can risk a small position for potentially large upside. NAMS falls in […] | IInsider Monkey | |
 Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. | ||
 Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. | ||
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates A week ago, NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) came out with a strong set of quarterly numbers that could... | ||
Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses? NewAmsterdam Pharma Company N.V. reported first-quarter 2026 results, with sales of US$3.04 million and a wider net loss of US$48.44 million compared with the same period a year earlier. Alongside these results, the company is asking shareholders to approve expanded share issuance authority and a new 2026 Employee Stock Purchase Plan, potentially reshaping its future financing and employee ownership profile. With the wider quarterly net loss in focus, we’ll now examine how these developments... | ||
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives described as encouraging trends in two-year blinded data and a lower-than-anticipated major | ||
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +13.66% and +35.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||